

Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended	
	September 30, 2021	September 30, 2020
Reconciliation of GAAP to Non-GAAP research and development:		
GAAP Research and development	\$ 194,572	\$ 161,783
Less: Stock-based compensation expenses	(12,417)	(13,703)
Less: Upfront payment on license and collaboration agreement	(10,000)	—
Non-GAAP Research and development	<u>\$ 172,155</u>	<u>\$ 148,080</u>
Reconciliation of GAAP to Non-GAAP selling, general and administrative:		
GAAP Selling, general and administrative	\$ 142,075	\$ 167,472
Less: Stock-based compensation expenses	(20,950)	(23,561)
Less: Costs associated with the strategic financing collaboration	—	(763)
Less: Loss on contractual settlement	—	(650)
Less: Change in estimate of contingent liabilities	—	(28,000)
Non-GAAP Selling, general and administrative	<u>\$ 121,125</u>	<u>\$ 114,498</u>
Reconciliation of GAAP to Non-GAAP operating loss:		
GAAP operating loss	\$ (181,677)	\$ (225,199)
Add: Stock-based compensation expenses	33,367	37,264
Add: Costs associated with the strategic financing collaboration	—	763
Add: Upfront payment on license and collaboration agreement	10,000	—
Add: Loss on contractual settlement	—	650
Add: Change in estimate of contingent liabilities	—	28,000
Non-GAAP operating loss	<u>\$ (138,310)</u>	<u>\$ (158,522)</u>